Thesis

Founded in 2017 and based in New York, US, Outliers Inc. , dba Thesis, operates as a provider of nootropic supplements that help users boost cognition as well as raise energy levels, feel motivated, clear brain fog, and increase focus. The company was founded by its CEO, Dan Freed. In April 2023, Thesis raised USD 13.

65 million in series A funding from Alive VC and Break Trail Ventures, including Unilever Ventures and Redo Ventures, valuing the company at USD 81. 13 million post-money. The company specializes in customized nootropic compounds that stimulate specific aspects of the brain. Thesis formulates nutrient molecules and gives personalized recommendations based on individual goals and unique brain chemistry, with a focus on improving mental performance.

The procedure starts with a quiz that examines individual needs and ambitions. Customers receive a beginning package including four blends to sample over the course of a month and can optimize their mixes with the help of wellness coaches and nootropics experts. The blends provided by Thesis are tailored to solve specific issues such as energy, attention, motivation, clarity, creativity, and reasoning. Thesis provides optimum bioavailability and excellent results for its consumers by utilising studied dosages and ingredients.

The firm offers ingredients including choline, ginkgo biloba, theobromine, lion’s mane, agmatine, NAC, and others. The organization plans to use the April 2023 funding to expand its product offerings, increase its workforce, and support clinical trials.